Navigation Links
MedImmune's Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
Date:8/23/2007

Native American infants, with an overall incidence and severity of adverse events (AEs) that were similar between the motavizumab and the placebo groups. The mortality rates were not statistically different between groups (0.4 percent in the placebo arm, n=2 and 0.3 percent in the motavizumab arm, n=3) and were not considered to be related to the study drug. As was suggested in the pivotal Phase 3 trial conducted in high-risk, preterm infants, rates of hypersensitivity related skin rashes within two days of dosing were seen in about one percent of treated children in the motavizumab group.

MedImmune's Commitment to RSV Prevention

MedImmune is a world leader in the development of innovative therapeutic biologic products to prevent RSV disease. In 1996, MedImmune launched the first anti-RSV drug, RespiGam(R) (respiratory syncytial virus immune globulin intravenous (human) (RSV-IGIV)), which was a polyclonal antibody administered via four-hour intravenous infusion. In 1998, MedImmune introduced Synagis, which was a significant product improvement as a monthly intramuscular injection for the prevention of severe RSV, as well as being the first MAb to receive U.S. Food and Drug Administration (FDA) approval for an infectious disease. With the development of motavizumab, MedImmune continues to reinforce its commitment to developing anti-RSV products. In a head-to-head comparative Phase 3 trial with Synagis, motavizumab met its primary endpoint of reducing RSV-related hospitalizations in high-risk pediatric patients and met its secondary endpoint of reducing medically attended, outpatient respiratory tract infections in that patient group. MedImmune is also developing a small-molecule product candidate to prevent RSV as well as a vaccine against RSV, both of which are in Phase 1 clinical trials.

About RSV

Each year, up to 125,000 infants in the U.S. are hospitalized with severe RSV infections, the leading cause of lower respiratory tract infections
'/>"/>

SOURCE MedImmune, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
2. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
3. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
4. Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke
5. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
6. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
7. New Analysis of WHI Data Shows Reduced Levels of Coronary Artery Calcification, a Predictor of Cardiovascular Events, in Women aged 50-59 taking Estrogen Therapy
8. Pivotal Phase III Trial Showed Promacta (eltrombopag olamine) Raised Platelet Counts and Reduced Bleeding in Patients With Chronic ITP
9. Preclinical Study Finds Protease Inhibitor-Resistant HIV May Have Reduced Potential to Develop Resistance to Panacos Bevirimat
10. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
11. Data Suggest Cymbalta Reduced Severity of Night Pain in Patients with Diabetic Nerve Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... 12, 2014 Research and Markets ... the "MEMS Gyroscopes Analog Devices ADIS16136 Precision ... to their offering. ... grade applications made a lot of progress in ... They are now accepted in high-reliability environments, and ...
(Date:12/15/2014)... and Markets ( http://www.researchandmarkets.com/research/32cmct/inferior_vena ) has announced ... Filters - Global Trends, Estimates and Forecasts, 2012-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 Global Inferior Vena Cava (IVC) ... 2016. The North America accounts ... Europe claims approximately 27% (2018). ...
(Date:12/15/2014)... , December 15, 2014 ... drugs for aggressive drug resistant cancers, today announces that ... a private placing from new and existing investors. ... to support the development of its pipeline of innovative ... for its lead drug candidate, BGB324, a first-in-class selective ...
Breaking Medicine Technology:MEMS Gyroscopes Analog Devices ADIS16136 Precision Angular Rate Sensor Reverse Costing Analysis 2Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 2Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 3Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 4BerGenBio Completes NOK90 Million Fundraising 2
... Reportlinker.com announces that a new market research report ... and Market of Xylose in China ... and the global financial crisis in Q4 2008, Chinese ... manufacturers suspended or even stopped production due to declining ...
... 19 Contact lenses improve vision-related quality of life ... of appearance and athletics, according to data drawn from ... and contact lenses on the self-perception of nearsighted children ... that the biggest improvement may be more considerable after ...
Cached Medicine Technology:Reportlinker Adds Production and Market of Xylose in China 2Reportlinker Adds Production and Market of Xylose in China 3Children Report Better Vision-Related Quality of Life with Contact Lenses vs. Glasses 2
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ) today ... FDA-approved diabetes drugs, BYETTA(R) (exenatide) injection and SYMLIN(R) (pramlintide ... once weekly at the American Diabetes Association,s (ADA,s) 69th ... June 5 to 9. The company will also host ...
... Spine Surgery Provides Better Diagnosis and Treatment for Patients ... L. Reed, M.D. performed the first revolutionary ... to treat acute and chronic back pain in Dallas ... the only doctors performing the procedure in the Dallas/Fort ...
... The British Red Cross are asking people,to pledge their support ... networks, instant messenger and email during,Refugee Week (15th-21st June). , ... a charity has created an online movement to,pledge support and ... Refugees arriving in the UK are often labelled as a ...
... the new treatments available for incontinence nowadays, an effective ... women struggling with incontinence. The main roadblock to that ... the severity of his condition. Dr. Peter Muench of ... too well and advises patients that full disclosure is ...
... American Diabetes Association , ... Welch, Minn. (Vocus) May ... the serious health issues that are associated with diabetes. Type 2 ... those who are 19 years and older. Diabetes has reached epidemic ...
... claims between November 2007 and October 2008, Only 2% of critical illness ... - cancer, heart related and stroke , ... Edinburgh, UK (PRWEB) May ... life insurance *, has today published details of its critical illness ...
Cached Medicine News:Health News:Amylin Pharmaceuticals to Present Compelling Efficacy and Safety Data From Diabetes Programs at ADA 2009 2Health News:Amylin Pharmaceuticals to Present Compelling Efficacy and Safety Data From Diabetes Programs at ADA 2009 3Health News:Amylin Pharmaceuticals to Present Compelling Efficacy and Safety Data From Diabetes Programs at ADA 2009 4Health News:Amylin Pharmaceuticals to Present Compelling Efficacy and Safety Data From Diabetes Programs at ADA 2009 5Health News:Amylin Pharmaceuticals to Present Compelling Efficacy and Safety Data From Diabetes Programs at ADA 2009 6Health News:Amylin Pharmaceuticals to Present Compelling Efficacy and Safety Data From Diabetes Programs at ADA 2009 7Health News:Kenneth L. Reed, M.D. Performs First State of the Art AccuraScope(TM) Procedure in Dallas 2Health News:Global Creative, Media and Technology Agency LBi Launches Cutting Edge Social Movement for the British Red Cross in Support of Refugee Week 2Health News:Delaware Urologic Associate's, Dr. Peter J. Muench, Presents Advances in Incontinence Treatment with a New Perspective and Outlook 2Health News:Delaware Urologic Associate's, Dr. Peter J. Muench, Presents Advances in Incontinence Treatment with a New Perspective and Outlook 3Health News:Delaware Urologic Associate's, Dr. Peter J. Muench, Presents Advances in Incontinence Treatment with a New Perspective and Outlook 4Health News:Prairie Island Indian Community Supports Fight Against Diabetes Locally and Nationally 2Health News:Scottish Widows Releases Critical Illness Cover Claims Figures 2
This book includes orthopedic, reproductive, renal, cardiovascular, GI, and respiratory problems; and other common conditions....
... enable all those involved with healthcare decisions ... very latest evidence in their field of ... each year as the volume of evidence ... delivering the best single source available for ...
Over 10,000 entries. This dictionary is both a home medical guide and as an aid for all those working in the medical and allied professions. The entries are laid out and jargon-free....
... for PDA is a combination of the Medical ... Dictionary pocket for PDA. The first part of ... overview of the Spanish language, i.e. pronunciation, common ... of anatomy and medical terminology. The second part ...
Medicine Products: